Get the Stockscreener App
67.87
1.32%
0.97
After Hours:
67.87
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $67.87, with a volume of 5.80M.
It is up +1.32% in the last 24 hours and down -9.54% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$66.90
Open:
$66.95
24h Volume:
5.80M
Relative Volume:
1.06
Market Cap:
$210.86B
Revenue:
$54.07B
Net Income/Loss:
$7.04B
P/E Ratio:
30.10
EPS:
2.255
Net Cash Flow:
$7.28B
1W Performance:
-0.13%
1M Performance:
-9.54%
6M Performance:
-12.34%
1Y Performance:
-3.35%
1-Day Range:
$66.87
$68.44
1-Week Range:
$66.59
$68.44
52-Week Range:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
67.87 | 210.86B | 54.07B | 7.04B | 7.28B | 2.255 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
astrazeneca reports breakthrough in breast cancer treatment By Investing.com - Investing.com India
astrazeneca reports breakthrough in breast cancer treatment - Investing.com
AstraZeneca: positive results in breast cancer - marketscreener.com
AstraZeneca Plc Enhertu trial hits key PFS goal - DirectorsTalk Interviews
AstraZeneca reports best trial results in a decade for metastatic breast cancer treatment - Proactive Investors
Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Omeprazole Market Is Booming Worldwide 2025-2032 | Astrazeneca Plc., Sandoz, Inc., Mylan N.V. - openPR.com
Should You Buy, Sell Or Hold AstraZeneca Stock Before Q1 Earnings? - Barchart.com
AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? - Yahoo
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients - Yahoo Finance
ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival Versus. THP As 1st-Line Therapy For Patients With HER2+ Metastatic Breast Cancer - marketscreener.com
AstraZeneca (AZN) Highlights Promising Trial Results for Enhertu in Breast Cancer Treatment | AZN Stock News - GuruFocus
AstraZeneca Touts Positive Survival Data for Enhertu Combo in Broad Breast Cancer Population - marketscreener.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Shows High-level Results in Late-stage Trial - marketscreener.com
Vasculitis Market Overall Study Report 2025-2032 | AstraZeneca - openPR.com
AstraZeneca Unit Hit With Antitrust Suit Over Soliris - Law360
AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters
AstraZeneca Unit Faces US Class Action Lawsuit Alleging Misuse of Soliris Patent - marketscreener.com
AstraZeneca Gets Backing to Trim Fired Worker’s Vaccine Bias Row - Bloomberg Law News
BNP Paribas Exane sets AstraZeneca stock to outperform, PT at GBP115 - Investing.com UK
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
European pharma companies issue demands to stay in EU ahead of expected US tariffs - MarketScreener
Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly - insights.citeline.com
AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib - Medical Dialogues
Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? - Yahoo Finance
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Nasdaq
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca : India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output - marketscreener.com
NICE recommends new combination breast cancer drug - MarketScreener
astrazeneca shareholders approve all resolutions at agm - Investing.com
Astrazeneca PLC Says All Resolutions Passed At AGM - MarketScreener
AstraZeneca’s AGM Approves All Resolutions, Marks Board Changes - TipRanks
Drug Tariffs Will Harm Patients, AstraZeneca Chairman Says - Bloomberg.com
AstraZeneca (AZN) Gains Momentum with EU Drug Approvals - GuruFocus
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle - Proactive financial news
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that - Proactive Investors
GLP-1 Market Top PlayersAstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech. - openPR.com
Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now? - Yahoo
AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatm - GuruFocus
AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer - GuruFocus
AstraZeneca Settles Covid-Shot Suit With Christian Salesman - Bloomberg Law News
AstraZeneca Blocks Generics Ahead Of Patent Dispute - Law360
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - Mitrade
AstraZeneca stock touches 52-week low at $61.76 - Investing.com
AstraZeneca stock touches 52-week low at $61.76 By Investing.com - Investing.com India
UK Regulator Approves Expanded Use of AstraZeneca's Targeted Cancer Therapy - MarketScreener
UK Approves Indication Extension for AstraZeneca-Daiichi Sankyo's Cancer Drug Enhertu - marketscreener.com
Barclays Keeps AstraZeneca at Overweight on Potential to Withstand Tariff Storm - MarketScreener
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):